Purpose Investments Launches the World-s First High Interest Savings ETF

TORONTO, ONTARIO -- (Marketwired) -- 10/15/13 -- Purpose Investments Inc. ("Purpose") is pleased to announce the…

Continue Reading

Micro-Cap Review Magazine Fall/Winter 2013 Issue Now Available on StockNewsNow.com and MicroCapReview.com

MARINA DEL REY, CA -- (Marketwired) -- 10/15/13 -- SNN Incorporated, a global financial publishing, media,…

Continue Reading

BrightScope Issues List of Top 20 Commodities Funds Held in America-s 401k Plans

Gives Investment Community All-New Visibility Into the Health of 401k Plans

Continue Reading

OTCBBJournal.com Issues a New Micro-Cap Stock Research Report

NEW YORK, NY -- (Marketwired) -- 10/15/13 -- (OTCQB: WWAG) through its subsidiary Summit Digital acquires…

Continue Reading

BlackRock(R) Announces October Monthly Cash Distributions for the iShares(R) Funds

TORONTO, ONTARIO -- (Marketwired) -- 10/15/13 -- (TSX: CAB)(TSX: CAB.A)(TSX: CBD)(TSX: CBD.A)(TSX: CBH)(TSX: CBH.A)(TSX: CBN)(TSX: CBN.A)(TSX:…

Continue Reading

DirectCash Payments Inc. Announces Regular Cash Dividend

CALGARY, ALBERTA -- (Marketwired) -- 10/15/13 -- DirectCash Payments Inc. (the "Company" or "DirectCash") (TSX: DCI)…

Continue Reading

DirectCash Payments Inc. Announces Third Quarter Conference Call

CALGARY, ALBERTA -- (Marketwired) -- 10/15/13 -- DirectCash Payments Inc. ("DirectCash" or the "Company")(TSX: DCI) hereby…

Continue Reading

Washington Federal Completes Fiscal Year With Record Earnings

SEATTLE, WA -- (Marketwired) -- 10/15/13 -- Washington Federal, Inc. (NASDAQ: WAFD), parent company of Washington…

Continue Reading

Gil Cohen of MetLife Earns Chartered Financial Consultant(R) (ChFC(R)) Designation, Finacial Planning-s Highest Standard

FT. LAUDERDALE, FL -- (Marketwired) -- 10/15/13 -- Gil Cohen, Market Leader, MetLife-s Cypress Financial Group,…

Continue Reading

Can-Fite BioPharma-s CF101 Drug Selected as one of the “Top Autoimmune/Anti-Inflammatory Disease Projects to Watch” by Elsevier Business Intelligence

CF101 Is Currently in Phase III Trials for Psoriasis and Phase II for Rheumatoid Arthritis

Continue Reading